Amendment Announcement by HOOKIPA Pharma
HOOKIPA Pharma Inc. has made an important announcement regarding an amendment to its previously disclosed Rule 2.9 information. This development reflects the company's commitment to accurate and transparent communication about its stock structure.
Details of the Share Structure Adjustment
The amendment concerns the ISIN of HOOKIPA's common stock, which was inaccurately stated in an earlier notification. The previous ISIN was cited as US43906K1007; however, the correct ISIN is US43906K2096. This change took effect following a 1-for-10 reverse stock split completed in July.
According to the latest confirmation, HOOKIPA has a total of 9,655,022 shares of Common Stock issued, each having a par value of $0.0001. Alongside the Common Stock, the company has issued several classes of preferred stock, including:
- 2,399,517 shares of Class A common stock,
- 370 shares of Series A convertible preferred stock,
- 10,800 shares of Series A-1 convertible preferred stock,
- 15,268 shares of Series A-2 convertible preferred stock.
Each Class A common stock shareholder has the option to convert ten shares into a single share of Common Stock. However, this is subject to restrictions that prevent ownership exceeding 4.99% after conversion. For preferred shareholders, conversion to Common Stock can happen at a rate of 100 shares for each preferred share, although similar ownership restrictions of 9.99% apply.
Restricted Stock Units and Financial Structure
HOOKIPA Pharma has issued 369,070 shares in the form of restricted stock units as part of its incentive plans to attract and retain top talent. This structure is essential for aligning employee interests with the company's long-term success.
Furthermore, the company confirms that it does not hold any relevant securities in treasury, showcasing its commitment to transparency and shareholder engagement. This clarity on equity stakes is crucial for investors evaluating their positions in HOOKIPA.
Contact Information for Investor Inquiries
For those interested in reaching out or seeking more information, HOOKIPA has provided a direct line for inquiries:
HOOKIPA Pharma Inc.
+43 1 890 63 60
Malte Peters, CEO
Terry Coelho, EVP & CFO
Email: IR@hookipapharma.com | Chuck@LifeSciAdvisors.com
Financial advisement for HOOKIPA is provided by Moelis & Company, supporting the company's navigation through regulatory frameworks and market strategies. For financial inquiries, contact:
Moelis & Company
+44 (0) 207 634 3500
Why This Announcement is Important
This announcement underscores HOOKIPA's ongoing efforts to maintain compliance with regulatory requirements and ensure that shareholders are well informed of any structural changes in equity. Such diligence plays a vital role in strengthening investor confidence and sustaining market integrity.
Frequently Asked Questions
What is the significance of the ISIN update?
The ISIN update corrects a previous error, ensuring accurate identification of HOOKIPA's common stock for investors and stock exchanges.
How many shares of common stock does HOOKIPA currently have?
HOOKIPA currently has 9,655,022 shares of common stock issued, alongside various classes of preferred stock.
Who can I contact for more information about HOOKIPA?
Interested parties can contact HOOKIPA directly at +43 1 890 63 60 or via email at IR@hookipapharma.com.
What restrictions apply to Class A common stock conversion?
Class A common stock holders may convert shares into common stock, but with restrictions to prevent ownership from exceeding 4.99% post-conversion.
Is there any treasury stock held by HOOKIPA?
HOOKIPA does not hold any relevant securities in treasury, emphasizing its transparent financial communication.
